Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker10Good day, everyone. Welcome to the Syndax fourth quarter 2025 earnings conference call. Today's call is being recorded. If you would like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.Speaker13Thank you, operator. Welcome, and thank you a ...

The weight-loss drug market has experienced incredible momentum over the past few years, and according to analyst projections, it hasn't peaked yet -- far from it. Among the many drugmakers looking to join this market is Altimmune (NASDAQ: ALT), a smaller biotech whose shares could skyrocket from their current levels if its leading program is successful. While the upside potential of a company like Altimmune is attractive, it's important to highlight that there is plenty of risk, too. A safer -- and argu ...

Corporate Presentation February 2026 Highly Purified Peptide/Protein Biosimilar Interchangeable Proprietary Injectables Inhalation Intranasal New Molecular Peptides Oncology Ophthalmology Rheumatology Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, of Amphastar Pharmaceuticals, Inc. ("Amphastar", "we". "our" and that are based on our management's current expectations and assumptions and on information currently available to management. ...

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference [Accessibility Statement] Skip NavigationWASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time.The corporate presentation given at the Citizens Life Sciences Conference may be access ...

Management is pivoting to a high-growth strategy by expanding sales capacity in priority geographies that exhibit favorable market access and established distributor relationships.Oncology performance remained a stable revenue base, with CINVANTI showing resilience against competitive pressures while the company continues the planned wind-down of SUSTOL.The implementation of permanent J-Codes for ZYNRELEF and APONVIE has improved reimbursement clarity, facilitating broader adoption across hospitals and ambu ...

Achieved record full-year net revenues of $780.6 million, a 24% increase driven by the first full year of Jornay PM ownership and continued growth in the core pain portfolio. Jornay PM delivered 48% revenue growth compared to pro forma 2024, supported by a strong back-to-school season and the initial impact of sales force expansion from 125 to 180 representatives. The pain portfolio, comprising Belbuca, Xtampza ER, and Nucynta, grew 6% year-over-year to $631.7 million, reinforcing management's view th ...

Puma Biotechnology Earnings Call Commercial Update February 26, 2026 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These ...

Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements ...

February 26, 2026 Fourth Quarter and Full Year 2025 Financial Results and Business Update Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively comme ...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026. Here’s what investors need to know.Aurinia Pharmaceuticals stock is feeling bearish pressure. What’s pressuring AUPH stock?Lupkynis Sales Drive Full-Year GrowthThe company reported fourth-quarter 2025 adjusted earnings of 26 cents a share, beating analysts' consensus of 22 cents and surging from one cent a ...